Design of P1′ and P3′ residues of trivalent thrombin inhibitors and their crystal structures

被引:13
|
作者
Sion-Usakiewicz, JJ [1 ]
Sivaraman, J [1 ]
Li, YG [1 ]
Cygler, M [1 ]
Konishi, Y [1 ]
机构
[1] Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada
关键词
D O I
10.1021/bi992419b
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Synthetic bivalent thrombin inhibitors comprise an active site blocking segment, a fibrinogen recognition exosite blocking segment, and a linker connecting these segments. Possible nonpolar interactions of the P1' and P3' residues of the linker with thrombin S1' and S3' subsites, respectively, were identified using the "Methyl Scan" method [Slon-Usakiewicz et al. (1997) Biochemistry 36, 13494-13502]. A series of inhibitors (4-tert-butylbenzenesulfonyl)-Arg-(D-pipecolic acid)-Xaa-Gly-Yaa-Gly-beta Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-(beta-cyclohexylalanine in which nonpolar P1' residue Xaa or P3' residue Yaa was incorporated, were designed and improved the affinity to thrombin. Substitution of the P3' residue with D-phenylglycine or D-Phe improved the K-i value to (9.5 +/- 0.6) x 10(-14) or 1.3 +/- 0.5 x 10(-13) M, respectively, compared to that of a reference inhibitor with Gly residues at Xaa and Yaa residues (K-i = (2.4 +/- 0.5) x 10(-11) M). Similarly, substitution of the P1' residue with L-norleucine or L-beta-(2-thienyl)alanine lowered the K-i values to (8.2 +/- 0.6) x 10-14 or(5.1 +/- 0.4) x 10(-14) M, respectively. The linker Gly-Gly-Gly-beta Ala of the inhibitors in the previous sentence was simplified with 12-aminododecanoic acid, resulting in further improvment of the K-i values to (3.8 +/- 0.6) x 10(-14) or (1.7 +/- 0.4) x 10(-14) M, respectively. These K-i values are equivalent to that of natural hirudin (2.2 x 10(-14) M), yet the size of the synthetic inhibitors (2 kD) is only one-third that of hirudin (7 kD). Two inhibitors, with L-norleucine or L-beta-(2-thienyl)alanine at the P1' residue and the improved linker of 12-aminododecanoic acid, were crystallized in complex with human alpha-thrombin. The crystal structures of these complexes were solved and refined to 2.1 Angstrom resolution. The Lys(60F) Side chain of thrombin moved significantly and formed a large nonpolar S1' subsite to accommodate the bulky P1' residue.
引用
收藏
页码:2384 / 2391
页数:8
相关论文
共 50 条
  • [41] Potent and selective bicyclic lactam inhibitors of thrombin: Part 2: P1 modifications
    Plummer, JS
    Berryman, KA
    Cai, C
    Cody, WL
    DiMaio, J
    Doherty, AM
    Edmunds, JJ
    He, JX
    Holland, DR
    Levesque, S
    Kent, DR
    Narasimhan, LS
    Rubin, JR
    Rapundalo, ST
    Siddiqui, MA
    Susser, AJ
    St-Denis, Y
    Winocour, PD
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (23) : 3409 - 3414
  • [42] Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors
    Young, MB
    Barrow, JC
    Glass, KL
    Lundell, GF
    Newton, CL
    Pellicore, JM
    Rittle, KE
    Selnick, HG
    Stauffer, KJ
    Vacca, JP
    Williams, PD
    Bohn, D
    Clayton, FC
    Cook, JJ
    Krueger, JA
    Kuo, LC
    Lewis, SD
    Lucas, BJ
    McMasters, DR
    Miller-Stein, C
    Pietrak, BL
    Wallace, AA
    White, RB
    Wong, B
    Yan, YW
    Nantermet, PG
    JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (12) : 2995 - 3008
  • [43] Noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at P1
    Lee, K
    Jung, WH
    Park, CW
    Park, HD
    Lee, SH
    Kwon, OH
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (07) : 1017 - 1022
  • [44] P1,P3 truncated analogs of oscillarin and their inhibitory activity against blood coagulation factors
    Hanessian, Stephen
    Guillemette, Sebastien
    Ersmark, Karolina
    CHIMIA, 2007, 61 (06) : 361 - 367
  • [45] Multiple timescale expansions for neutron kinetics -: II:: Illustrative application to P1 and P3 equations
    Merk, BR
    Cacuci, DG
    NUCLEAR SCIENCE AND ENGINEERING, 2005, 151 (02) : 194 - 211
  • [46] P1 AND P3 PROTEINS OF INFLUENZA-VIRUS ARE REQUIRED FOR COMPLEMENTARY RNA-SYNTHESIS
    PALESE, P
    RITCHEY, MB
    SCHULMAN, JL
    JOURNAL OF VIROLOGY, 1977, 21 (03) : 1187 - 1195
  • [47] Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position
    Tucker, TJ
    Brady, SF
    Lumma, WC
    Lewis, SD
    Gardell, SJ
    Naylor-Olsen, AM
    Yan, YW
    Sisko, JT
    Stauffer, KJ
    Lucas, BJ
    Lynch, JJ
    Cook, JJ
    Stranieri, MT
    Holahan, MA
    Lyle, EA
    Baskin, EP
    Chen, IW
    Dancheck, KB
    Krueger, JA
    Cooper, CM
    Vacca, JP
    JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (17) : 3210 - 3219
  • [48] New renin inhibitors with pseudodipeptidic units in P1-P1′ and P2′-P3′ positions
    Paruszewski, R
    Jaworski, P
    Winiecka, I
    Tautt, J
    Dudkiewicz, J
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2002, 50 (06) : 850 - 853
  • [49] Rational curves on K3 surfaces in P1 x P1 x P1
    Baragar, A
    PROCEEDINGS OF THE AMERICAN MATHEMATICAL SOCIETY, 1998, 126 (03) : 637 - 644
  • [50] Thermodynamic criterion for the conformation of P1 residues of substrates and of inhibitors in complexes with serine proteinases
    Qasim, MA
    Lu, SM
    Ding, JH
    Bateman, KS
    James, MNG
    Anderson, S
    Song, JK
    Markley, JL
    Ganz, PJ
    Saunders, CW
    Laskowski, M
    BIOCHEMISTRY, 1999, 38 (22) : 7142 - 7150